MCM
CRDL

MAI Capital Management’s Cardiol Therapeutics CRDL Stock Holding History

MAI Capital Management’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-25
Closed -$32 – 3468
2024
Q4 		$32 Buy
+25
New +$42 ﹤0.01% 3458

Other funds holding CRDL

TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
LSA
Lion Street Advisors Austin, Texas $289M AUM 3.13% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
AI
Atria Investments Charlotte, North Carolina $8.94B AUM 20.84% 1-Year Est. Return
MOS
MGO One Seven Beachwood, Ohio $4.98B AUM 22.72% 1-Year Est. Return

MAI Capital Management's CRDL Position: Q1 2025 in Review

MAI Capital Management sold out of Cardiol Therapeutics (CRDL) in Q1 2025, closing a stake of 25 shares — an estimated $32 sold.

MAI Capital Management first reported a position in CRDL in Q4 2024 and held it in 1 quarter. The position peaked at $32 in Q4 2024. 38 funds tracked by Wall St. Rank hold CRDL as of Q1 2025.

  • MAI Capital Management reported no remaining Cardiol Therapeutics position as of Q1 2025 after selling out during the quarter.
  • MAI Capital Management sold 25 Cardiol Therapeutics shares in Q1 2025, an estimated $32.
  • MAI Capital Management first reported a position in Cardiol Therapeutics in Q4 2024 and held it in 1 quarter.
  • MAI Capital Management's Cardiol Therapeutics position peaked at $32 in Q4 2024.
  • 38 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2025.

Based on MAI Capital Management's 13F filing for Q1 2025, filed 15 May 2025.